The initial success of the copyright undeniably reshaped the medication landscape, but betting in companies primarily reliant on off-patent versions presents a uncertain picture. While early earnings were substantial, the expiration of patents and the appearance of cheaper alternatives have diminished sales. Consequently, a thorough analysis of cur